Glutathione is a tripeptide (glutamate, cysteine, and glycine) that occurs naturally in human cells and participates in redox reactions and cellular detoxification pathways. In compounding, it is prepared as an injectable or intravenous formulation for administration in clinical settings, distinct from the oral dietary-supplement forms sold over the counter.
Among longevity- and wellness-oriented practices that source through ScriptLinkRx, compounded glutathione ranks as the #14 most-prescribed compounded product, based on cumulative order volume across clinics ordering through ScriptLinkRx as of mid-2026. It also carries a specific compliance history: the FDA has documented quality failures in compounded glutathione injectables, which makes sterile-compounding standards the central consideration for any provider evaluating it.
What Glutathione Is
Glutathione (often abbreviated GSH in its reduced form) is an endogenous antioxidant tripeptide synthesized in the liver and present in every cell of the body. Biochemically, it functions as a substrate for glutathione peroxidase and glutathione-S-transferase enzymes, participating in the neutralization of reactive oxygen species and in phase II conjugation reactions involved in hepatic metabolism.
In compounding, glutathione is typically the reduced L-glutathione form. It is worth noting a regulatory nuance: a monograph for glutathione exists in the United States Pharmacopeia as a dietary ingredient, which is not the same as a drug-substance monograph. This distinction matters because the sterile-compounding of an injectable drug requires an API suitable for that purpose, not a dietary-supplement-grade powder. As discussed below, the difference has been at the center of documented adverse events.
How Providers Use It in Practice
Compounded glutathione is ordered predominantly by longevity, wellness, aesthetic, and integrative practices, frequently as part of IV-therapy or intramuscular-injection service lines. Some providers incorporate it into protocols framed around oxidative stress or hepatic detoxification pathways, and it is sometimes offered alongside other IV micronutrient preparations.
This article does not describe or endorse any specific therapeutic use. Glutathione is not an FDA-approved drug for any indication, and the clinical evidence base for injectable glutathione across the conditions for which it has been nominated—ranging from oxidative stress to chemotherapy side-effect reduction—was characterized by the FDA as limited when the substance was reviewed for the compounding bulks list. Any decision to prescribe rests on the individual provider's clinical judgment and the patient-specific documentation that compounding under Section 503A requires.
Notably, this article does not address cosmetic or skin-lightening uses. Providers should be aware that marketing injectable glutathione for skin-lightening raises distinct regulatory and safety concerns and is outside the scope of a neutral clinical discussion.
Forms and Combinations Available Through Compounding
Compounding pharmacies prepare glutathione in several dosage forms so that a prescriber can match the route and concentration to a documented patient need. Commonly available forms include:
- Intravenous (IV) solutions, prepared for administration in a clinical setting.
- Intramuscular (IM) or subcutaneous injectable vials, for in-office or, where appropriate, take-home administration.
- Combination IV preparations, in which glutathione is a component of a broader micronutrient or antioxidant infusion.
- Non-sterile forms such as oral capsules and intranasal sprays, ordered where a prescriber documents a patient-specific need for a non-injectable route.
The rationale for compounding—rather than dispensing a commercial product—is that no FDA-approved injectable glutathione drug product exists on the U.S. market. Compounding allows a specific concentration, volume, preservative-free formulation, or route to be tailored to an individual patient. That customization is the legitimate basis for compounding; it is not a pathway to mass-produced, one-size-fits-all inventory. This article intentionally omits strengths, concentrations, and administration schedules, which are clinical decisions for the prescriber and pharmacist.
Regulatory Status and Provider Considerations
Compounded glutathione is not an FDA-approved drug, and compounded preparations are not reviewed by the FDA for safety, effectiveness, or manufacturing quality before they reach patients. Providers should never represent compounded glutathione as FDA-approved or as equivalent to an approved product.
Two regulatory threads are relevant as of July 2026:
1. Bulks-list status. Glutathione has been evaluated for the Section 503A list of bulk drug substances that can be used in compounding. In June 2022, the Pharmacy Compounding Advisory Committee (PCAC) voted to recommend adding glutathione to the final 503A bulks list, even though the FDA had recommended against inclusion, citing a lack of effectiveness and safety data. The FDA has not finalized a rule adopting that recommendation. Under the agency's interim policy on compounding with bulk drug substances—updated effective January 7, 2025—substances that were placed in the interim "Category 1" may continue to be used by compounders until the FDA either finalizes their inclusion or formally declines to include them. Providers should confirm current status with their pharmacy partner, because the bulks-list picture can change.
2. Documented quality failures. The most important glutathione-specific consideration is the FDA's history of flagging contamination in compounded glutathione injectables. In February 2019, the FDA warned compounders not to use L-glutathione powder distributed by Letco Medical to compound sterile drugs after adverse events were reported. The agency was aware of seven patients who experienced reactions—ranging from nausea and vomiting to low blood pressure and difficulty breathing severe enough to require hospitalization—following intravenous administration of compounded glutathione. Testing linked the events to bacterial endotoxin contamination, with reported levels well above the appropriate limit. The powder involved had been labeled "Caution: Dietary Supplement," which is not suitable for compounding sterile injectables. The FDA has separately reminded compounders to use ingredients appropriate for sterile compounding and has highlighted concerns specific to using dietary-ingredient glutathione for that purpose.
The practical takeaway for prescribers: the risk profile of compounded glutathione is dominated by sourcing and sterility, not by the molecule itself. A provider's due diligence should focus heavily on the pharmacy's API sourcing and sterile-compounding controls.
Clinics order compounded medications through platforms like ScriptLinkRx, which connect licensed practices with licensed 503A/503B partner pharmacies; the platform does not replace a provider's own verification of the pharmacy's quality systems.
Sourcing and Quality: What to Ask a Compounding Pharmacy
Given the documented endotoxin history, a rigorous sourcing conversation is essential. Providers evaluating a pharmacy partner for compounded glutathione should confirm:
- API grade and source. Is the glutathione API a pharmaceutical-grade bulk drug substance—not a dietary-supplement-grade powder—accompanied by a valid Certificate of Analysis (CoA) from an FDA-registered manufacturer?
- Endotoxin and sterility testing. Does each sterile lot undergo bacterial endotoxin testing and sterility testing? Ask specifically about endotoxin limits, given the 2019 events.
- USP compliance. Does the pharmacy compound in accordance with USP General Chapters <795> (non-sterile), <797> (sterile), and <800> (hazardous drugs) as applicable? Injectable glutathione falls squarely under <797>.
- Potency and stability testing. Is finished-preparation potency verified, and is beyond-use dating supported by stability data rather than assigned by default?
- Facility licensure and inspection. Is the pharmacy licensed in the state where the patient is treated, and—if a 503B outsourcing facility—is it registered with the FDA and subject to cGMP inspection?
- Recall and adverse-event history. Has the pharmacy or its API supplier been subject to FDA warning letters, recalls, or 483 observations related to sterile compounding?
Documenting these answers is a reasonable part of a provider's own quality file.
Frequently Asked Questions
Is compounded glutathione FDA-approved?
No. There is no FDA-approved injectable glutathione drug product, and compounded glutathione is not reviewed by the FDA for safety, effectiveness, or quality before use. It should not be described to patients as FDA-approved or as equivalent to an approved medication.
Why does the FDA have specific concerns about compounded glutathione?
In 2019, the FDA linked seven adverse-event reports to compounded glutathione injections contaminated with bacterial endotoxin, traced to a dietary-supplement-grade powder that was not suitable for sterile compounding. The episode made sterile-compounding controls and API sourcing the defining quality issue for this product.
Can any bulk glutathione powder be used to compound an injectable?
No. Dietary-supplement-grade glutathione is not appropriate for sterile injectables. Compounding requires a pharmaceutical-grade bulk drug substance with a valid Certificate of Analysis from an FDA-registered manufacturer, prepared under USP <797> sterile standards with endotoxin and sterility testing.
Is glutathione on the 503A bulks list?
As of July 2026, the FDA has not finalized glutathione's inclusion on the 503A bulks list. PCAC recommended adding it in 2022, over the FDA's own recommendation against inclusion. Its interim usability depends on the FDA's ongoing bulk-substances policy, so providers should confirm current status directly with their pharmacy.
What is the single most important question to ask a pharmacy about glutathione?
Ask whether every sterile lot is released only after passing bacterial endotoxin and sterility testing, using a pharmaceutical-grade API with a CoA. That control directly addresses the failure mode behind the documented adverse events.
Related Reading
- See where glutathione ranks among the most-prescribed compounded medications
- Compounded NAD+: forms and provider considerations
- GHK-Cu copper peptide: regulatory status and provider considerations
Sources
- FDA. "FDA highlights concerns with using dietary ingredient glutathione to compound sterile injectables." https://www.fda.gov/drugs/human-drug-compounding/fda-highlights-concerns-using-dietary-ingredient-glutathione-compound-sterile-injectables
- FDA. "FDA warns compounders not to use glutathione from Letco Medical to compound sterile drugs." https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-compounders-not-use-glutathione-letco-medical-compound-sterile-drugs
- FDA. "FDA reminds compounders to use ingredients suitable for sterile compounding." https://www.fda.gov/drugs/human-drug-compounding/fda-reminds-compounders-use-ingredients-suitable-sterile-compounding
- FDA. "Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act." https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
- Federal Register. "Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act; Guidance for Industry; Availability" (Jan. 7, 2025). https://www.federalregister.gov/documents/2025/01/07/2024-31546/interim-policy-on-compounding-using-bulk-drug-substances-under-section-503a-of-the-federal-food-drug
- PMC/NIH. "Seven cases of probable endotoxin poisoning related to contaminated glutathione infusions." https://pmc.ncbi.nlm.nih.gov/articles/PMC6088536/
